Prognostic model in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy

被引：0
|
作者：
Radosavljevic, D. Z. [1 ]
Gavrilovic, D. [1 ]
Golubicic, I. [1 ]
Jelic, S. [1 ]
机构：
[1] Inst Oncol & Radiol Serbia, Belgrade, Serbia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18046
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PROGNOSTIC IMPORTANCE OF RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Radosavljevic, D.
    Kezic, I.
    Jelic, S.
    Golubicic, I.
    ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [2] Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?
    Daga, H.
    Takeda, K.
    Kiyota, H.
    Tokunaga, S.
    Nanjo, S.
    Sumitani, M.
    Shoji, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Yi, S. Y.
    Ahn, M.
    Park, J. Y.
    Lee, H. R.
    Lee, J.
    Park, Y. H.
    Ahn, J. S.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Sazdanic-Velikic, Danica
    Tepavac, Aleksandar
    Lalic, Nensi
    Stojkovic, Ivana
    Secen, Nevena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S914 - S914
  • [5] Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Wenheng
    Mao, Yan
    Zhan, Yongzi
    Huang, Jianheng
    Wang, Xiangping
    Luo, Penghui
    Li, Li
    Mo, Dunchang
    Liu, Qiong
    Xu, Huimin
    Huang, Changjie
    ONCOLOGY LETTERS, 2016, 11 (01) : 723 - 730
  • [6] INTRINSIC AND ACQUIRED RESISTANCE PATTERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Stewart, David J.
    Saintigny, Pierre
    Lu, Charles
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S862 - S863
  • [7] GENETIC BIOMARKERS IN THE VEGF PATHWAY AS PROGNOSTIC FACTORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Riera, P.
    Sullivan, I
    Andres, M.
    Majem, M.
    Artigas, A.
    Barnadas, A.
    Salazar, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 92 - 93
  • [8] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [9] Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Sullivan, Ivana
    Salazar, Juliana
    Majem, Margarita
    Pallares, Cinta
    del Rio, Elisabeth
    Paez, David
    Baiget, Montserrat
    Barnadas, Agusti
    CANCER LETTERS, 2014, 353 (02) : 160 - 166
  • [10] NANOG Predicts Poor Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Lee, Seung Hyeun
    Park, Myung Jae
    Park, So Young
    In, Kwang Ho
    Kim, Chul Hwan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S959 - S960
12345